Search for a trial

Reirradiation for recurrent lung cancer in the thorax: overall survival, local control, and toxicity: a phase 2 trial

The objective of the study is to give a dose of 45 to 60 Gy and therefore to prolong the survival in patients with recurrent lung cancer.

A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease Small-Cell Lung Cancer (SCLC)

To assess the efficacy of durvalumab +tremelimumab + EP treatment compared with EP in terms of OS and the efficacy of durvalumab + EP treatment compared with EP in terms of OS

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (MS200647-0037)

To demontrate improvement of progression-free survival (PFS) and/or overall survival (OS) with M7824 compared with pembrolizumab in first-line participants with advanced NSCLC with high PD-L1 tumor expression.

A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer

To determine FRAME-001-specific immune responses in peripheral blood after administration of FRAME-001 to patients with advanced NSCLC.Secondary objectives- To assess safety and tolerability of FRAME-001.- To evaluate clinical anti-tumor response to…

Tumormarkers in diagnostics and follow up of lungcarcinoma

This study aims to prospectively evaluate the diagnostic properties and clinical value of the protein tumor markers CEA, CA15.3, Cyfra21.1, HE4, NSE, proGRP en SCC and the molecular tumormarkers EGFR, ALK, KRAS and BRAF in diagnosing, and monitoring…

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

The study will look at patients with chemotherapy-naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC). The research aims to compare a new drug called nivolumab OR nivolumab with ipilimumab (another cancer drug) OR nivolumab combined with…

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CACZ885V2301, CANOPY-2)

Primary: Safety run-in part (part 1):* to confirm tthe recommended Phase 3 dose regimen (RP3R) of canakinumab in combination with docetaxel. Double-blind, randomized, placebo-controlled part (part 2):* to compare the overall survival (OS) between…

An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib

Primary: 1. Effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, AUCmean, Cmax and CminSecondary objective 1. Safety of the CYP3A4 moderator ritonavir in combination with erlotinib,…

Continuous and Bi-level positive airway pressure for motion mitigation of intra-thoracic tumors treated with radiotherapy

The main objective of this pilot study is to evaluate the effect of motion mitigation with BiPAP or CPAP on tumor motion during the course of radiotherapy in patients with intra-thoracic tumors.

Erector Spinae Plane Block versus Thoracic Epidural Block in Elective Video-Assisted Thoracic Surgery (VATS): A Prospective Randomized Open Label non-inferiority Trial

Evaluate the non-inferiority of the ESP-block compared to the TEA in VATS lobectomy or wedge resection.

Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.

A) To quantify the difference in 18F-FDG uptake (expressed as SUVmax, SUVmean and SUVpeak) in tumor lesions within 7 days before and between 7 and 14 days after treatment initiation with immune checkpoint inhibitors with or without chemotherapy. B)…

Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736).

The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736).

Multicenter pilot study to determine the feasibility of a multimodal prehabilitation program in patients with non-small cell lung cancer undergoing anatomical lung resection

To determine whether the multimodal prehabilitation program (without extending the time from MDT meeting to operation beyond the DLCA-S norm of 3 weeks) for patients with NSCLC undergoing anatomical lung resection in MMC and ASz:1. is feasible 2.…

Combining SBRT and pembrolizumab in early stage non-small cell lungcancer patients planned for surgery: exploring safety and immunological proof of principle.

To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…

FDG-PET for avoidance of futile neck dissections after non-surgical treatment of advanced head and neck cancer

To study the diagnostic accuracy of FDG PET and MRI as a function of time in the response monitoring and detection of residual lymph node metastases after non-surgical treatment of advanced head and neck cancer.

A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)

Primary: • To assess the Major Pathological Response (MPR) rate (<= 10% of residual viable tumor cells) on the resected specimen at the time of surgery in all subjects randomized to canakinumab alone or in combination with pembrolizumab.…

Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor

To assess the progression-free survival rate at 12 months (PFSR12) to lorlatinib in ALK positive advanced NSCLC patients, who progressed on second generation ALK-TKI with the presence of ALK resistance mutations on blood (liquid biopsies) by…

A prospective, randomized study comparing chemotherapy versus chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer with low cTML and oncogenic driver,STK11 or KEAP1 mutation and a PD-L1 TPS<50%.

To compare the objective response rate between patients with metastatic non-small cell lung cancer characterized by PDL-1 TPS&lt;50% and low cTML (&lt;300 nonsynonymous mutations) and either actionable mutation, inactivating STK11 or KEAP1…

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

This study has been transitioned to CTIS with ID 2023-508214-42-00 check the CTIS register for the current data. Primary: To compare the efficacy of AMG 510 versus docetaxel as assessed by progression-free survival (PFS) in previously treated…

The value of combined Quantitative MRI for Treatment Response Assessment in head and neck cancer patients receiving (Chemo)radiotherapy.

We will measure correlations between serially measured MRI parameters (pretreatment and early during treatment) and therapy outcome (response, locoregional recurrence and overall survival) in patients with HNSCC undergoing chemoradiation (CRT)…